e-learning
resources
Virtual 2020
Tuesday, 08.09.2020
Antibiotic therapy for pneumonia and pleural infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Biofilm formation by Pseudomonas aeruginosa in empyema
J. Liang (Nan ning, China), Z. Zhang (Nan ning, China), J. Li (Nan ning, China), J. Kong (Nan ning, China), W. Ke (Nan ning, China)
Source:
Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections
Session:
Antibiotic therapy for pneumonia and pleural infections
Session type:
Oral Presentation
Number:
4666
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Liang (Nan ning, China), Z. Zhang (Nan ning, China), J. Li (Nan ning, China), J. Kong (Nan ning, China), W. Ke (Nan ning, China). Late Breaking Abstract - Biofilm formation by Pseudomonas aeruginosa in empyema. 4666
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Efficacy of Ceftolozane/Tazobactam in Comparison with Piperacillin/Tazobactam in Severe Pseudomonas aeruginosa Pneumonia Swine Model
Source: International Congress 2019 – Clinical challenges in respiratory infection
Year: 2019
Pseudomonas aeruginosa
pneumonia in the community
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Should pseudomonas aeruginosa be the main target in bronchiectasis?
Source: International Congress 2016 – Monitoring comorbidities
Year: 2016
Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors?
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Bayer Expert Forum at ERS 2014 ‘Infection, Exacerbation and Colonisation: Managing
Pseudomonas aeruginosa
in non-CF Bronchiectasis’ – Full Video
Source: International Congress 2014 – Bayer Expert Forum at ERS 2014 ‘Infection, Exacerbation and Colonisation: Managing
Pseudomonas aeruginosa
in non-CF Bronchiectasis’ – Full Video
Year: 2014
Pseudomonas aeruginosa
colonisation in patients without bronchiectasis
Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura
Year: 2014
Eradication of Pseudomonas aeruginosa in cystic fibrosis
Source: Eur Respir J 2006; 27: 438-439
Year: 2006
Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Pulmonary infections with pseudomonas aeruginosa
Source: Eur Respir J 2004; 24: Suppl. 48, 642s
Year: 2004
Pseudomonas aeruginosa from CF airways uses various strategies to outcompete staphylococcus aureus
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors
Source: Eur Respir J 2010; 35: 598-615
Year: 2010
Variation in hydrogen cyanide production between different strains of Pseudomonas aeruginosa
Source: Eur Respir J 2011; 38: 409-414
Year: 2011
Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty?
Source: Eur Respir J 2010; 35: 473-474
Year: 2010
Molecular mechanisms and virulence of colistin-resistant klebsiella pneumoniae
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016
Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Pseudomonas, enterobacteriaceae ESBL positive and staphylococcus MRSA: When to suspect them in CAP?
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Eradication of Pseudomonas aeruginosa in cystic fibrosis patients
Source: Eur Respir J 2006; 27: 653
Year: 2006
Respiratory commensal streptococcus spp do not modulate the outcome of pseudomonas aeruginosa infection in vivo
Source: International Congress 2016 – Cystic fibrosis: various aspects
Year: 2016
Antimicrobial activity of N-acetylcysteine against Stenotrophomonas maltophilia and Burkholderia cepacia complex grown in planktonic phase and in biofilm
Source: International Congress 2017 – How can microbiology and translational research help physicians?
Year: 2017
Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre
Source: Eur Respir J 2005; 25: 474-481
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept